Functional Downregulation of PD-L1 and PD-L2 by CpG and non-CpG Oligonucleotides in Melanoma Cells

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Immune checkpoint inhibitors are crucial for treating metastatic melanoma.
• Tumor cells can evade immune responses through checkpoint molecules like PD-L1/2.
• Oligonucleotides (ODNs) are known immune response modulators.

Purpose of the Study:

• To investigate the impact of ODNs on the expression of PD-L1 and PD-L2 (PD-L1/2) in melanoma.
• To identify specific ODN characteristics that influence PD-L1/2 expression.
• To elucidate the mechanism by which ODNs modulate PD-L1/2 expression.

Main Methods:

• IFNγ-stimulated melanoma cell lines (A375, SK-Mel-28) were treated with various synthetic ODNs.
• ODNs varied in sequence, length, and phosphorothioate (PTO) backbone composition.
• PD-L1/2 expression was analyzed at protein, mRNA, and promoter levels.

Main Results:

• Several ODN sequences significantly suppressed PD-L1/2 expression.
• The suppressive effect was dependent on ODN length and PTO backbone.
• A guanine-rich ODN (nCpG-6-PTO) demonstrated high efficacy in downregulating PD-L1/2.
• ODNs with G-quartet motifs were shown to suppress the JAK/STAT/IRF1 interferon signaling axis.

Conclusions:

• Specific ODNs can effectively downregulate PD-L1/2 expression in melanoma cells.
• ODNs targeting the interferon signaling pathway represent a promising therapeutic strategy.
• These findings identify ODNs as potential pharmacological agents to overcome tumor immune escape.